Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
about
Animal models of hemophiliaCurrent animal models of hemophilia: the state of the artLessons Learned from Animal Models of Inherited Bleeding Disorders.A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophiliaBio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)Long-term expression of canine FVIIa in hemophilic dogsRecurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancyEradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection.Portal vein delivery of viral vectors for gene therapy for hemophilia.Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B.Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs.rFVIIa transported from the blood stream into tissues is functionally active.Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVIIAnimal models of hemophilia and related bleeding disorders.Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.Therapeutic plasma proteins--application of proteomics in process optimization, validation, and analysis of the final product.Gene therapy for haemophilia: a long and winding road.The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies.Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.Animal models of FVIIa gene expression: their role in the future development of haemophilia treatmentMuscle Gene Therapy for Hemophilia.An engineered U1 small nuclear RNA rescues splicing defective coagulation F7 gene expression in mice.The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency.Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility.Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).Animal models: Dogged pursuit.Models for assessing immunogenicity and efficacy of new therapeutics for the treatment of haemophilia.Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.
P2860
Q27012571-C96C1B72-6B5F-4B15-8CCA-DC9E79DCE842Q28072423-580ED8C6-A53C-4F9B-837A-C7F402CD13D3Q30409863-F645F775-280D-4D79-87DC-DFABB552E1EBQ30442996-50A97242-CF8B-4D2C-8095-EDE6B25E0FFBQ30443003-4188D5A6-3E57-4CA9-8ECB-A26A3D020D0DQ33768400-FA184F1C-FBB1-40F3-8B66-B1CAC1B5633BQ33802667-7FFC2D89-927E-4C1E-8474-B92CC201227AQ34249813-1180018D-921C-4840-A0AA-E2DBE0A369D1Q34541550-41CFBD8D-ECCE-4E8F-8CE4-2A3B0D11F871Q34707273-1A989B90-FDBD-4A81-87D7-D6C91B4AD5A2Q34795284-5CA4D1C6-332C-41DF-B888-9510EE2ECDA6Q35006603-898592E9-6C05-4DF7-B272-3F5BFA42C938Q35006608-DA280696-E6AE-4002-8478-FD375191C310Q35174932-4A7115A1-45BE-4179-A6E0-F5F6A1529C37Q35755627-09B1807D-5743-4765-8739-9ECDBCCC6687Q36171849-449C6191-DD86-42C0-A955-358C0F46AAD4Q36547796-0385B778-7DBE-4C36-B99E-CE705022F420Q37091290-8666A15A-6C06-4C89-AD95-412A6FF5DC39Q37586365-2D2AF23F-93F0-4C59-BFCE-394388204ACAQ37872258-58A6B6C3-E161-47B0-B513-CF8EB3D02607Q37903924-FD513C22-3599-49B8-8407-D201464FB6E2Q38539938-47FDE929-F3BA-4B35-892D-4DD6E889B1DCQ38754256-C7A1706B-AAB2-42C1-99F3-AB6CAB1DA8E1Q39591239-2DE17783-99B5-4AD2-8079-E2EB1D554CD6Q39898071-DF106104-397F-4A7E-BC5D-EB1FF4056A3DQ40055959-996CAB7E-E0E9-4065-8C68-9EA3B05FB166Q42224211-6B81FEEE-022D-45B9-8BE1-9E477B558F4EQ42791749-C3EF3933-3979-4AD2-BBB0-536643FF4CD8Q45855465-27F20DB6-6CBC-4A8E-B92C-F18991F55185Q45859525-9AC68E1A-3AA3-4B53-81A9-E608DECB34D3Q45869314-D17747C0-9EAD-4DDB-961A-6FEB81408FD3Q45870490-D152BE99-C1C3-45CB-9EAF-89E07D1DBCDBQ45879922-5D62AFE6-7B7A-4AA6-A58F-4260FA110064Q55471442-A4ACEB71-93F5-4576-B657-82ACF2FFD03B
P2860
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
@en
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
@nl
type
label
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
@en
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
@nl
prefLabel
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
@en
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
@nl
P2093
P2860
P1433
P1476
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
@en
P2093
Aaron Dillow
Elizabeth Merricks
Harre D Downey
Katherine A High
Majed N Aljamali
Mirella Ezban
Paris Margaritis
Shangzhen Zhou
Timothy C Nichols
P2860
P304
P356
10.1182/BLOOD-2008-07-168377
P407
P577
2008-12-23T00:00:00Z